Kadimastem Announces Positive Interim Results from Phase 2 in ALS
Kadimastem leadership and the cell product manufacturing process. Israel-based Kadimastem, a biotechnology company developing cell therapies for the treatment of severe debilitating diseases announced positive interim results from the Phase 2 clinical trial. The company’s lead product, AstroRx, showed a positive efficacy signal and a good safety profile in a clinical Cohort B Phase 1/2a […]
Continue Reading